Important tool in our rare disease toolbox: hybrid retrospective-prospective natural history studies serve well as external comparators for rare disease studies

Natural history studies (NHS) can support regulatory decision-making at different stages of the drug product life cycle and are especially important in the context of rare diseases, which are associated with not only delayed or erroneous diagnoses but also a lack of approved treatments. Real-world e...

Descrición completa

Detalles Bibliográficos

Principais autores:	Chinenye Ugoji, Julien Heidt, Joan Largent, Emily Bratton, Laura Hester, Sareh Keshavarzi, Stuart Turner, Christina Mack
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Drug Safety and Regulation
Assuntos:	rare disease natural history studies real-world data hybrid design external comparators clinical development
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fdsfr.2024.1418050/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!